(October 2, 2024) Next Generation Bioprinting Platform: A Multimodal Approach for Bioprinting of Cartilaginous Multicellular Spheroids and Skin
The Next-Generation Bioprinting (NGB) Platform is designed to combine the advantages of Laser-Assisted Bioprinting (LAB) technology—such as high resolution and enhanced cell viability— with other bioprinting technologies like bioextrusion.
This integration enables the fabrication of complex multi-cellular 3D constructs. Featuring robotic automation and innovative fluidics devices, the NGB platform enables transition of the bioprinted products from the laboratory to clinic. The commercial NGB-R system is designed for developing bioprinting procedures at the preclinical stage that are translatable to the clinical-ready NGB-C system. This system complies with Good Manufacturing Practices (GMP) for Advanced Therapy Medicinal Products (ATMPs).
In this webinar, we will showcase this translation capacity through bioprinting of skin and cartilaginous multicellular spheroids for building larger tissue structures.
About the Speaker (s)
Dr. Fabien Guillemot is a scientist-turned-entrepreneur, CEO and Founder of Poietis, whose mission is to develop and market the Next-Gen Bioprinting platform to bring Tissue Engineering therapies to patients. Fabien has an over 20 years experience in the field of Biofabrication. He holds a PhD in Material Science (INSA, 2000) and an Habilitation in Health and Life Sciences (Bordeaux University, 2010). He was appointed Researcher at INSERM, France in 2005, and invited researcher at Harvard University in 2010. Bioprinting pioneer and inventor (with 100+ publications and 13 patents), he left for entrepreneurship via training at HEC-Paris and founded Poietis in 2014.